Also known as: insulin human
MiniMed completed its $538 million IPO as its separation from Medtronic advances, with shares trading on the Nasdaq. Medtronic submitted the next-generation MiniMed Flex insulin pump to the FDA and reported a 14.8% year-over-year revenue increase for its Diabetes business. The full separation is expected to be complete by the end of calendar year 2026.
Sequel Med Tech reported positive pivotal trial results for its twiist Automated Insulin Delivery System in adults with type 2 diabetes. The 13-week study showed meaningful improvements in HbA1c and time in range with no severe hypoglycemia events. Separately, Sequel and Senseonics launched the twiist system integrated with Eversense 365 CGM across the U.S.
Tandem Diabetes Care secured expanded CE mark approval in Europe for its Control-IQ automated insulin delivery systems, covering adults with type 2 diabetes and type 1 diabetes during pregnancy. The approvals follow FDA clearance in the US and are supported by clinical trial data showing improved glucose control.
MannKind Corporation announced FDA approval of Afrezza inhaled mealtime insulin for pediatric patients with diabetes ages 6 and older. The approval makes Afrezza the first needle-free mealtime insulin alternative for children in over 100 years. Eligible patients can access Afrezza for $35 or less per month.
FDA approves MannKind's Afrezza inhaled insulin for children aged 6+ with type 1 and type 2 diabetes. Separately, an updated label provides new starting dose guidance for adults switching from injections or insulin pumps.
Tent5a was identified as a positive regulator of insulin production in pancreatic beta cells. Overexpression extended poly(A) tails of insulin transcripts and increased insulin content.
Microgravity drug research is expanding from ISS crystal studies to commercial manufacturing efforts. New experiments and a Varda-United Therapeutics collaboration target improved drug stability, delivery and production.
Insulin list prices rose more than 300% over two decades as PBMs face growing scrutiny over rebates, spread pricing, and transparency. Reform efforts and pharmacist involvement are central to drug affordability and access.
An experimental gut procedure helped a small group of patients maintain up to 80% of weight loss after stopping tirzepatide. A larger trial involving more than 300 people is underway.
GLP-1 drugs used for type 2 diabetes and obesity are seeing rising demand for weight loss as safety concerns also draw attention. A 2025 WHO guideline said long-term safety data remains limited.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07548996 |
Open-Label Study of Dimethyl Fumarate in Adults With Type 1 Diabetes |
RECRUITING | PHASE2/PHASE3 |
| NCT07494084 |
Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance |
NOT_YET_RECRUITING | PHASE4 |
| NCT07460336 |
Effects of Cofrogliptin on Beta-Cell Function in LADA Patients |
NOT_YET_RECRUITING | NA |
| NCT07432581 |
Topical Insulin Dressing on Management of Diabetic Foot Ulcers |
COMPLETED | NA |
| NCT07293715 |
Permissive Versus Strict Intrapartum Glucose Management in Type 1 Diabetes (PRISM-T1D) |
RECRUITING | PHASE4 |
| NCT07259564 |
A Study of GS3-007a for Oral Suspension in the Diagnosis of Adult Growth Hormone Deficiency (AGHD) |
TERMINATED | PHASE2 |
| NCT06781775 |
GDM: Insulin with or Without Metformin? |
RECRUITING | PHASE4 |
| NCT06762314 |
Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes |
RECRUITING | PHASE2 |
| NCT06699810 |
Modeling Ketosis-Prone Diabetes Remission Via Diverse Mechanisms of Glucotoxicity |
ACTIVE_NOT_RECRUITING | PHASE4 |
| NCT06601101 |
Effects of Topical Insulin on Corneal Epithelium Healing After Corneal Crosslinking in Patients With Keratoconus |
RECRUITING | PHASE3 |
